Recent Updates
Recently added Catalysts

Stem cells

Phase 3

Rheumatoid Arthritis Aggravated | Cell Therapies | Immunology |Takeda Pharmaceutical Company Limited|Trials Updated: Apr 12, 2019

Stem cells development status

Highest phase Phase 3 run by Hackensack Meridian Health (NCT01877837)
Phase scored for TAKPhase 1/2
Registered trials 2 across 2 sponsors since Aug 2012

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment53

FDA Designations

No designations recorded

Stem cells clinical trials

Stem cells · 1 trial · 1 indication

Phase 1/2 1
NCT01663116Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis PatientsRheumatoid Arthritis Aggravated
COMPLETED53 Analytics
PHASE1/PHASE2COMPLETED
Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients
Rheumatoid Arthritis AggravatedUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Adverse Events and Severe Adverse Events
6 months follow up after the first administration

Total number of Adverse Events and Severe Adverse Events, related and non-related with the medication will be recorded as a measure of tolerability and safety.

Secondary Endpoints

Proportion of ACR20 patients/ACR50 patients/ACR70 patients (swollen joints*, tender joints**, physician global assessment***, patient global assessment***, patient´s assessment of pain ***, ESR/CRP, HAQ score)
At selection and screening visit, and once per month during 6 months after the last administration
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
TreatmentEXPERIMENTAL1. first cohort: 1 million stem cells/kg administered at days 1, 8 and 15 2. second cohort: 2 million stem cells / kg administered at days 1, 8 and 15 3. third cohort: 4 million stem cells / kg administered at days 1, 8 and 15
PlaceboPLACEBO_COMPARATORLactate Ringer´s solution

Interventions

NameTypeDescription
Stem cellsGENETIC1. first cohort: 1 million stem cells/kg administered at days 1, 8 and 15 2. second cohort: 2 million stem cells / kg administered at days 1, 8 and 15 3. third cohort: 4 million stem cells / kg administered at days 1, 8 and 15
PlaceboGENETIC1. first cohort: 20 ml administered at days 1, 8 and 15 2. second cohort: 40 ml administered at days 1, 8 and 15 3. third cohort: 80 ml administered at days 1, 8 and 15
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites23

Inclusion criteria Patients must meet all the following inclusion criteria to be eligible for study entry: 1. Must understand and voluntarily sign an informed consent form prior to the conduct of any study related assessment/procedures. 2. Subjects with RA under treatment with at least one non-bio...

Countries:Spain
Unlock Eligibility Criteria

Frequently asked questions about Stem cells

What is Takeda's stem cell therapy used for?

Takeda Pharmaceutical Company Limited is developing a stem cell therapy for rheumatoid arthritis aggravated, an inflammatory joint condition. The program is in Phase 1 clinical development as a cell therapy in the immunology therapeutic area. It is an investigational treatment and has not been approved for commercial use.

Who is developing this stem cell therapy for rheumatoid arthritis?

Takeda Pharmaceutical Company Limited, which trades under the ticker TAK, is the developer of this stem cell therapy for rheumatoid arthritis aggravated. The program is in Phase 1 and is being studied as a cell therapy in the immunology therapeutic area.

What phase is Takeda's stem cell therapy in?

Takeda's stem cell therapy for rheumatoid arthritis aggravated is in Phase 1 clinical development. It is an investigational cell therapy and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed.

What clinical trial has been conducted for Takeda's stem cell therapy?

The stem cell therapy has been evaluated in one completed Phase 1 trial, NCT01663116, titled Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients. The trial enrolled 53 participants in Spain, was randomized and placebo-controlled, and included adults 18 years and older of all sexes.

How does Takeda's stem cell therapy work?

Takeda's stem cell therapy is an investigational cell therapy being studied for rheumatoid arthritis aggravated. It is designed to be administered intravenously, as reflected in the completed Phase 1 trial NCT01663116. The specific molecular target or mechanism of action has not been disclosed.